How to buy Decibel Therapeutics stock

Decibel Therapeutics, Inc is a biotechnology business based in the US. Decibel Therapeutics shares (DBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Decibel Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.

Decibel Therapeutics share price

Use our graph to track the performance of DBTX stocks over time.

Decibel Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$9.25 - $24.39
50-day moving average	$11.85
200-day moving average	$13.74
Wall St. target price	$28.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Decibel Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Decibel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Decibel Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Decibel Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-40.97%
Return on equity TTM	-145.27%
Profit margin	0%
Book value	N/A
Market capitalisation	$235.8 million

TTM: trailing 12 months

Shorting Decibel Therapeutics shares

There are currently 581,341 Decibel Therapeutics shares held short by investors – that's known as Decibel Therapeutics's "short interest". This figure is 9% up from 533,498 last month.

There are a few different ways that this level of interest in shorting Decibel Therapeutics shares can be evaluated.

Decibel Therapeutics's "short interest ratio" (SIR)

Decibel Therapeutics's "short interest ratio" (SIR) is the quantity of Decibel Therapeutics shares currently shorted divided by the average quantity of Decibel Therapeutics shares traded daily (recently around 151786.1618799). Decibel Therapeutics's SIR currently stands at 3.83. In other words for every 100,000 Decibel Therapeutics shares traded daily on the market, roughly 3830 shares are currently held short.

To gain some more context, you can compare Decibel Therapeutics's short interest ratio against those of similar companies.

• Pandion Therapeutics (PAND.US): 0.55
• Idera Pharmaceuticals (IDRA.US): 0.6
• Leap Therapeutics (LPTX.US): 1.6

However Decibel Therapeutics's short interest can also be evaluated against the total number of Decibel Therapeutics shares, or, against the total number of tradable Decibel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Decibel Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Decibel Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0373% of the tradable shares (for every 100,000 tradable Decibel Therapeutics shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Decibel Therapeutics.

Find out more about how you can short Decibel Therapeutics stock.

Decibel Therapeutics share dividends

We're not expecting Decibel Therapeutics to pay a dividend over the next 12 months.

Decibel Therapeutics overview

Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc.

Frequently asked questions

• What percentage of Decibel Therapeutics is owned by insiders or institutions?

  Currently 9.285% of Decibel Therapeutics shares are held by insiders and 31.398% by institutions.

• How many people work for Decibel Therapeutics?

  Latest data suggests 40 work at Decibel Therapeutics.

• When does the fiscal year end for Decibel Therapeutics?

  Decibel Therapeutics's fiscal year ends in December.

• Where is Decibel Therapeutics based?

  Decibel Therapeutics's address is: 1325 Boylston Street, Boston, MA, United States, 02215